HC Wainwright Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $35.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 275.94% from the company’s previous close.

STOK has been the subject of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Leerink Partners started coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Finally, Chardan Capital initiated coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 target price for the company. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $9.31 on Wednesday. The stock has a market capitalization of $493.12 million, a PE ratio of -4.43 and a beta of 0.95. Stoke Therapeutics has a one year low of $4.09 and a one year high of $17.58. The business’s fifty day moving average price is $12.12 and its 200-day moving average price is $13.14.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, equities analysts expect that Stoke Therapeutics will post -2.03 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel Jonathan Allan sold 9,696 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the sale, the general counsel now owns 35,142 shares in the company, valued at approximately $449,114.76. This trade represents a 21.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 13,945 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the completion of the transaction, the insider now owns 47,332 shares of the company’s stock, valued at $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Lynx1 Capital Management LP increased its position in shares of Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares during the last quarter. RTW Investments LP boosted its stake in Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after buying an additional 427,447 shares in the last quarter. State Street Corp grew its position in Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after acquiring an additional 1,123,500 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Stoke Therapeutics by 550.1% in the 2nd quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock worth $15,686,000 after acquiring an additional 982,451 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.